Eating soy-rich food can decrease the risk of bone fractures in pre-menopausal breast cancer survivors, suggests a new study. The higher soy intake was linked to 77 per cent reduced risk of osteoporotic fractures in younger women, the study showed.
In the study, published in JNCI Cancer Spectrum journal, researchers at Yale University investigated the impact of exercise and soy food consumption on bone fracture rates among breast cancer survivors.
“The menopausal transition is known to be a period of high risk for bone loss, and given the relative scarcity of data related to fracture risk among younger women with breast cancer, this study marks an important contribution to this body of literature,” said the paper’s lead author, Evelyn Hsieh, Assistant Professor at Yale University.
“Our findings, in particular regarding the protective effects of soy food consumption, provide novel insight into how future interventions can be best tailored to different risk groups,” Hsieh said.
For the study, the team used data from the Shanghai Breast Cancer Survival study of 5,042 newly diagnosed breast cancer survivors in the age group of 20-75.
The study found soy-based foods that are rich in isoflavones provide a natural selective estrogen receptor modulator (SERM), which helps in increasing the bone mineral density.
Previous studies have showed the use of tamoxifen, a SERM or drug, that is prescribed for breast cancer patients, reduces risk of fractures.
Several treatments for breast cancer can cause premature menopause and decrease bone mineral density, leading to a higher incidence of osteoporosis-related fractures among survivors compared with healthy women in the same age group.
Breast cancer is the second most common cancer among women in the US, with one in eight women diagnosed with it during their lifetime. (IANS)
Breast cancer in men is rarely seen. It shares many similarities with cancer of the breast in women but there are some important differences too.
Male breast cancer represents between 0.5 and 1 per cent of all breast cancers diagnosed each year. Higher rates of male cancer in central and eastern Africa may be related to higher liver infectious diseases that lead to hypoestrogenism.
Dr Kumardeep Dutta Choudhury, Senior Consultant & Head of Department, Dept of Medical Oncology (IOSPL), Fortis Hospital, Noida, shares the facts you need to know about it.
Risk factors associated with breast cancer in men:
Genetics and family history
Family history of cancer in a first-degree relative is associated with an increased risk of breast cancer among men. Approximately 15 to 20 per cent of men with breast cancer have a family history of the disease compared with only 7 per cent of the general male population.
The risk is higher with inherited BRCA2 rather than BRCA1 mutations. Other genes which have been associated with an increased risk of breast cancer in men are PTEN tumor suppressor gene (Cowden syndrome), tumor protein p53 (TP53; Li-Fraumeni syndrome), partner and localizer of BRCA2 (PALB2), and mismatch repair genes (Lynch syndrome).
Alterations of the estrogen to androgen ratio
Excessive estrogen stimulation may be due to hormonal therapies (e.g., estrogen-containing compounds or testosterone), hepatic dysfunction, obesity, marijuana use, thyroid disease, or an inherited condition, such as Klinefelter syndrome may increase risk of male breast cancer.
Primary testicular conditions
Testicular conditions may increase risk of breast cancer in men include orchitis, undescended testes (cryptorchidism), and testicular injury.
Male breast cancer has been diagnosed at a more advanced stage than female breast cancer, due to a lack of awareness. They generally present with a painless, firm mass that is usually subareolar, with nipple involvement in 40 to 50 percent of cases. The left breast is involved slightly more often than the right, and less than 1 percent of cases are bilateral. There may be associated skin changes, including nipple retraction, ulceration, or fixation of the mass to the skin or underlying tissues. Axillary nodes are typically palpable in advanced cases.
Most histologic subtypes of that cancer seen in women are also present in men, men with breast cancer are rarely diagnosed with lobular carcinomas is due to lack of acini and lobules in the normal male breast, although these can be induced in the context of estrogenic stimulation.
Approach to treatment in men is same as that for women. However, role of breast conserving surgery is limited because of small volume of breast tissue. In hormone receptor-positive disease, we give adjuvant tamoxifen rather than an aromatase inhibitor (AI), because of insufficient evidence to support AI monotherapy for men. If there are contraindications to tamoxifen (e.g., hypercoagulable state), an AI with GnRHa may be administered. AIs do not reduce testicular production of estrogens, that’s why GnRHa is administered concurrently with AI. They are treated with mastectomy, radiotherapy, chemotherapy and hormone therapy.
Limited data suggest these patients are at an increased risk of a contralateral breast cancer, but absolute risk is low. They are also at risk for secondary malignancies and 12.5 percent may develop a second primary cancer. The most common types were gastrointestinal, pancreas, non-melanoma skin, and prostate cancer.
Ten-year disease-specific survival rates for histologically negative nodes – 77 and 84 per cent, one to three positive nodes – 50 and 44 per cent and four or more histologically positive nodes – 24 and 14 per cent. (IANS)